Cardiovascular-Kidney-Metabolic Interactions and More: Multimorbidity and the Era of Integrated Care, Including the Barry M. Brenner, MD, Endowed Lectureship
Back to course
Video Transcription
Video Summary
Asset Subtitle

Moderator(s): Charles Ginsberg, Susanne Nicholas

Presentation(s):
  • SGLT2 Inhibitors: Cardiometabolic Renal Drugs for the Ages: The Barry M. Brenner, MD, Endowed Lectureship - Ralph DeFronzo
  • Nephrology and Eye Care in Diabetes - Merlin Thomas
  • Kidney-Liver Pharmacotherapies: What Is the State of the Art? - Arun Sanyal
  • Rheuma-Nephrology: Protecting Bones, Joints, and Nephrons - Austin Stack
ASN gratefully acknowledges Monarch Pharmaceuticals for support of the Brenner Endowed Lectureship.

Note: Continuing education credits are not being offered for this session.
Meta Tag
Date 11/6/2025
Pathway 1 Diabetic Kidney Disease
Pathway 2 Pharmacology
Session ID 507082
Keywords
Barry Brenner
glomerular hyperfiltration
progressive kidney disease
Brenner and Rector’s The Kidney
renal fibrosis
SGLT2 inhibitors
cardiorenal metabolic drugs
phlorizin
renal–hepatic axis
EMPA-REG OUTCOME
heart failure outcomes
intrarenal hemodynamics
diabetic retinopathy screening
MASLD/MASH and CKD
gout and urate-lowering therapy